U.S. emergency approval broadens use of Gilead's COVID-19 drug remdesivir


Source: Reuters


WASHINGTON (Reuters) - Gilead Science Inc’s (GILD.O) antiviral drug remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration for COVID-19 on Friday, clearing the way for broader use of the drug in more hospitals around the United States.

remdesivir.jpg, May 2020


During a meeting in the Oval Office of the White House with President Donald Trump, Gilead Chief Executive Daniel O’Day called the move an important first step and said the company was donating 1.5 million vials of the drug to help patients.

The donation is expected to be enough for at least 140,000 patients, depending on the number of days they need to be treated.

Gilead said on Wednesday the drug, which is given by intravenous infusion, had helped improve outcomes for patients with COVID-19, the respiratory disease caused by the novel coronavirus, and provided data suggesting it worked better when given earlier in the course of infection.




Cont'd.

LINK:
https://www.reuters.com/article/us-health-coronavirus-usa-fda-idUSKBN22D69R

Discusiones sobre el mismo tema

URL de retroenlace : https://www.ictal.org/index.php?trackback/1996

Fuente de los comentarios de esta entrada